GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GeneDx (Nasdaq: WGS), a genomic insights company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, from January 12-16. The company's management will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT.
The presentation will be accessible through live and archived webcasts on the company's investor relations website. GeneDx specializes in providing genetic diagnoses through advanced exome and genome tests, leveraging one of the world's largest rare disease data sets to deliver personalized healthcare solutions and improve drug discovery and healthcare system efficiency.
GeneDx (Nasdaq: WGS), un'azienda specializzata in informazioni genomiche, ha annunciato la sua partecipazione al 43° Congresso Annuale J.P. Morgan Healthcare a San Francisco, CA, dal 12 al 16 gennaio. La direzione dell'azienda terrà una presentazione mercoledì 15 gennaio 2025, alle 16:30 ora del Pacifico.
La presentazione sarà disponibile tramite webcast in diretta e registrati sul sito web delle relazioni con gli investitori dell'azienda. GeneDx si specializza nella fornitura di diagnosi genetiche attraverso test avanzati di esoma e genoma, sfruttando uno dei più grandi set di dati sulle malattie rare al mondo per offrire soluzioni sanitarie personalizzate e migliorare la scoperta di farmaci e l'efficienza del sistema sanitario.
GeneDx (Nasdaq: WGS), una empresa de análisis genómicos, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco, CA, del 12 al 16 de enero. La dirección de la empresa realizará una presentación el miércoles 15 de enero de 2025, a las 4:30 p.m. PT.
La presentación será accesible a través de webcast en vivo y grabados en el sitio web de relaciones con inversores de la empresa. GeneDx se especializa en proporcionar diagnósticos genéticos mediante pruebas avanzadas de exoma y genoma, aprovechando uno de los conjuntos de datos más grandes del mundo sobre enfermedades raras para ofrecer soluciones de atención médica personalizadas y mejorar el descubrimiento de fármacos y la eficiencia del sistema de salud.
GeneDx (Nasdaq: WGS), 유전체 통찰력 회사가 제43회 연례 J.P. Morgan 헬스케어 콘퍼런스에 참여한다고 발표했습니다. 이 행사는 1월 12일부터 16일까지 샌프란시스코, CA에서 열립니다. 회사 경영진은 2025년 1월 15일 수요일 오후 4:30 PT에 발표를 합니다.
발표는 회사의 투자자 관계 웹사이트를 통해 실시간 및 기록된 웹캐스트로 접근할 수 있습니다. GeneDx는 고급 엑솜 및 게놈 테스트를 통해 유전적 진단을 제공하며, 세계에서 가장 큰 희귀질환 데이터 세트를 활용하여 개인 맞춤형 의료 솔루션을 제공하고 약물 발견 및 의료 시스템 효율성을 향상시키는 데 중점을 둡니다.
GeneDx (Nasdaq : WGS), une entreprise spécialisée dans les informations génomiques, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco, CA, du 12 au 16 janvier. La direction de l'entreprise présentera une intervention le mercredi 15 janvier 2025, à 16h30 PT.
La présentation sera accessible via des webcasts en direct et enregistrés sur le site web des relations investisseurs de l'entreprise. GeneDx se spécialise dans la fourniture de diagnostics génétiques grâce à des tests avancés d'exome et de génome, s'appuyant sur l'un des plus grands ensembles de données sur les maladies rares au monde pour fournir des solutions de santé personnalisées et améliorer la découverte de médicaments ainsi que l'efficacité du système de santé.
GeneDx (Nasdaq: WGS), ein Unternehmen für genomische Einblicke, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco, CA, vom 12. bis 16. Januar bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 15. Januar 2025, um 16:30 Uhr PT eine Präsentation halten.
Die Präsentation wird sowohl in Echtzeit als auch als aufgezeichnetes Webcast über die Investor-Relations-Website des Unternehmens zugänglich sein. GeneDx hat sich auf die Bereitstellung genetischer Diagnosen durch fortschrittliche Exom- und Genomtests spezialisiert und nutzt einen der größten Datensätze für seltene Krankheiten der Welt, um personalisierte Gesundheitslösungen anzubieten und die Arzneimittelentdeckung sowie die Effizienz des Gesundheitssystems zu verbessern.
- None.
- None.
Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216905665/en/
Investor Relations Contact:
investors@GeneDx.com
Media Contact:
press@GeneDx.com
Source: GeneDx
FAQ
When is GeneDx (WGS) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access GeneDx's (WGS) J.P. Morgan Healthcare Conference presentation?
What is GeneDx's (WGS) main focus in genomic testing?
How does GeneDx (WGS) contribute to healthcare improvement?
